High-resolution computed tomography shows evidence of ILD.
The ACR/CHEST ILD Guidelines in Practice, a video
In collaboration with the American College of Chest Physicians, the ACR released two new comprehensive guidelines aimed at improving the screening, monitoring, and treatment of patients with interstitial lung disease (ILD) secondary to systemic autoimmune rheumatic diseases (SARDs). Recently, Sindhu R. Johnson, MD, PhD, professor of medicine at the University of Toronto, Canada, director of the Toronto Scleroderma Program and principal investigator for the guideline, and Elana J. Bernstein, MD, MSc, Florence Irving associate professor of medicine in the Division of Rheumatology at Columbia University, New York City, and co-first author, presented a webinar to talk about how the guidelines were developed and present some of the recommendations and their rationale: Watch the recording now!
A phase 3 trial described in The New England Journal of Medicine (NEJM) highlights the potential of a C5a receptor inhibitor, avacopan, for anti-neutrophil cytoplasmic antibody (ANCA) associated vasculitis.1 Avacopan may potentially offer a steroid-sparing option for the treatment of this serious disease. Current Treatment of ANCA-Associated Vasculitis Morbidity and mortality from ANCA-associated vasculitis have…
In a randomized, controlled trial, the risk difference between groups is interpreted as a causal effect of the treatment, according to Seoyoung C. Kim, MD, ScD, MSCE, an associate professor of medicine in the Division of Pharmacoepidemiology and Pharmacoeconomics and the Division of Rheumatology, Inflammation and Immunity at Brigham and Women’s Hospital and Harvard Medical…
The new Twitter account enables quick communication between ACR advocacy staff and ACR/ARP members about the policies, regulations and legislation that affect rheumatology patients and providers and how members can get involved.
At a virtual event with the chair of the Ways & Means Subcommittee on Health, RheumPAC donors were able to share concerns and recommendations about drug pricing policies and how they affect providers and patients.
The ACR is advocating against policies that threaten patient access and disrupt practice workflow, including non-medical switching, tapering patients off biologics, specialty pharmacy acquisition mandates and site-of-service restrictions.
Bright spots from this legislative session include utilization management reform, copay accumulator bans and pharmacy benefit manager reform.
RA shortens life expectancy, even with advances in treatment—and more so for women than for men, according to new research by Chiu et al.
The 21st Century Cures Act (Cures Act) became law on Dec. 13, 2016, and emphasized interoperability in the exchange of healthcare information between healthcare providers, health information entities and patients. The Cures Act underscored unimpeded access to patient electronic health information (EHI) upon request, in a manner that is secure and updated automatically, and prohibits…
The Lupus and Allied Diseases Association Inc. established the Marc R. Chevrier, MD, PhD, FACR, Lupus Research Memorial Fund at the Rheumatology Research Foundation, effective March 1. This fund was established to honor the life and legacy of Marc Chevrier, MD, PhD, FACR, a pioneer and patient advocate in the field of lupus. About Dr….
As we emerge from the grips of a global pandemic, we are taking this opportunity to pause and reflect on the ARP and what our division brings to the care of our patients. I found the words of Amanda Gordon’s inaugural reading of her poem, “The Hill We Climb,” inspirational and instructive for our past,…